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Available online 21 October 2015Neutrophils provide innate immune defence against microbes such
as bacteria. Neutrophilic airway inﬂammation is a characteristic feature
of chronic obstructive pulmonary disease (COPD) (Hogg et al., 2004), a
condition that is commonly caused by cigarette smoking. Neutrophils
activated by the inhalation of toxic particles contribute to the patho-
physiology of COPD by secreting proteases that cause tissue destruction
and by releasing mediators that promote airway inﬂammation. On the
one hand, it could be therapeutically beneﬁcial to reduce neutrophil
activity in COPD lungs. On the other hand, onehas to be careful about pre-
serving anti-bacterial defence. This is particularly relevant for the subset
of COPD patients who have persistent bacterial colonisation and/or
acute bacterial exacerbations, often caused by nontypeable Haemophilus
inﬂuenzae (NTHi) or Streptococcus pneumoniae (Desai et al., 2014).
The chemokine receptor CXCR2 plays a key role in neutrophil chemo-
taxis. The CXCR2 antagonist MK-7123 administered for 6 months re-
duced sputum neutrophil numbers and improved lung function in
COPD patients (Rennard et al., 2015), supporting the concept that reduc-
ing neutrophilic airway inﬂammation is beneﬁcial for COPD patients.
However, this orally administered drug excessively reduced blood neu-
trophil counts in some patients. Furthermore, thereweremore infections
in the optional 12 month extension period in patients treated with MK-
7123 compared to placebo. This highlights the balance required with
anti-neutrophil therapies in COPD; potential clinical beneﬁt weighed
against risk of infection.
Th17 cytokines, including IL-17 and IL-22, ﬁght bacteria by various
mechanisms, including the upregulation of anti-microbial proteins and
the secretion of neutrophil chemokines, such as CXCL8, by airway epi-
thelial cells (McAleer and Kolls, 2014). Th17 cytokines are produced
by various cell types, including conventional lymphocytes and type 3 in-
nate lymphoid cells, in response to the secretion of IL-1β, IL-23 and IL-6
by antigen presenting cells (APCs). IL-17A is themost well studied Th17
cytokine in COPD; the expression of this cytokine is increased in theom.2015.09.040.
. This is an open access article underlungs of stable COPD patients compared to controls (Eustace et al.,
2011; Di Stefano et al., 2009). Roos et al. showed that IL-17A levels
were increased during acute exacerbations of COPD, but only when
NTHi was present (Roos et al., 2015). Roos et al. also demonstrated
that cigarette smoke (CS) exposed mice (for 4 days or 8 weeks) had
greater IL-17A levels and lung neutrophilia after exposure to NTHi com-
pared to room air (RA) exposed mice. This excessive neutrophilic re-
sponse was absent when an anti-IL17A neutralising antibody was
administered, andwhen IL-17A knockoutmicewere used. Interestingly,
these knockout mice did not have a defect in NTHi bacterial clearance.
The authors suggest that targeting IL-17A may be beneﬁcial during
COPD exacerbations, because of the potential to reduce neutrophilic in-
ﬂammation while having no detrimental effect on bacterial clearance.
In EBioMedicine, Pichavant et al. used 12 week CS exposure to gener-
ate mice with COPD-like lung disease (Pichavant et al., 2015). There
was increased neutrophilic inﬂammation and bacterial load after S.
pneumoniae exposure in CS compared to room air (RA) exposed mice.
Furthermore, there were lower IL-17 and IL-22 levels in infected CS-
exposedmice, and lower levels of the Th17 inducers IL-1β and IL-23 pro-
duced by APCs. The suppressive effect of CS on various cytokines has also
been observed in previous human studies using COPD lung cells, such as
macrophages (Metcalfe et al., 2014). IL-22 administration before bacterial
challenge increased bacterial clearance in CS exposedmice. Therewas no
change in lung neutrophil numbers, but there were increased levels of
anti-microbial peptides and IL-17 production, and less histological evi-
dence of S. pneumoniae associated lung damage. IL-17 was not adminis-
tered to combat bacterial infection, as this cytokine may contribute to
COPD pathophysiology (Eustace et al., 2011; Di Stefano et al., 2009;
Roos et al., 2015). These results strongly suggest a role for IL-22 in pro-
moting anti-bacterial immunity in the context of chronic cigarette
smoke exposure. Experiments using peripheral blood mononuclear cells
showed defective IL-17 and IL-22 secretion from COPD compared to con-
trol cells after exposure to S. pneumoniae, providing validation of mouse
model results by using relevant cells from patients with disease.
These studies by Roos et al. (Roos et al., 2015) and Pichavant et al.
(Pichavant et al., 2015) provide potentially important insights into the
complex interactions between Th17 cytokines, neutrophilia and bacte-
rial exposure in COPD. In CS-exposed mice, NTHi and S. pneumoniae in-
fection both caused enhanced lung neutrophilia, but IL-17 production
was enhanced with the former and decreased with the latter. There
may be differences between the experimental details of the mouse CS
exposure protocols, such as duration of CS exposure, that could alterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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response was increased by bacterial exposure, but the IL-17 response
was bacterial species dependent. Furthermore, both papers convincing-
ly back upmouse datawith results fromCOPDpatients.Where does this
leave us with the potential for targeting IL-17, given its potential pro-
inﬂammatory role in COPD? It seems that suppressing IL-17 may be a
useful anti-inﬂammatory approach in the context of NTHi infection,
but not during S. pneumoniae infection.
Would pharmacological modulation of IL-22 be beneﬁcial in COPD
patients? There appears to be a defect in the IL-22 response to S.
pneumoniae in COPD patients, and animal model data suggests that
modulating IL-22 levels improves bacterial clearance and inﬂammation
in a manner that does not involve any change in neutrophil numbers
(Pichavant et al., 2015). It would be important to know if this defect in
IL-22 production is also present after exposure to NTHi in COPD patients
and animal models.
We are becoming increasingly aware of the heterogeneous nature of
COPD, with speciﬁc treatments being required for subsets of patients
with distinct characteristics (Woodruff et al., 2015). The endotype con-
cept, a group of patients deﬁned by a biological mechanism, allows
pharmacological targeting ofmechanisms rather than clinical character-
istics (Woodruff et al., 2015). Targeting thedefective IL-22 response to S.
pneumoniae would be an example of endotype-driven treatment.
Targeting the excessive IL-17 response to NHTiwould be another exam-
ple. The therapeutic index (beneﬁt versus risk) of such approaches will
be enhanced by deﬁnition of the patients most likely to beneﬁt. As we
move into the era of personalised medicine, one size will not ﬁt all in
COPD.
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